NCT02169713View on ClinicalTrials.gov

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Healthy SubjectsPharmacokineticsDrug-Drug Interaction (DDI)

Interventions

DRUG

Mirabegron

Oral

DRUG

Solifenacin succinate

Oral

DRUG

Tamsulosin HCl

Oral

DRUG

Placebo

Oral

Trial Locations (1)

14050

Parexel International GmbH, Berlin

All Listed Sponsors

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02169713 - Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects | Biotech Hunter | Biotech Hunter